Supplementary Material and Methods ; Supplementary Figures 1-8; Supplementary Table 1 from Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC

Supplementary Data Supplementary Material and Methods: Tumor experiments; CpG-B toxicity in vitro assay; Effect of i.t. CpG-B treatment on the growth of a distal tumor; Reactive oxygen species (ROS) detection. Supplementary Figures: Supplementary Figure 1 shows that CpG-B does not impact EG7 cell growth in vitro; Supplementary Figure 2 depicts that intratumoral CpG-B{plus minus}OVAII administration of B16-OVA tumors significantly inhibits tumor growth; Supplementary Figure 3 illustrates that 5 days following intratumoral CpG-B{plus minus}OVAII administration, EG7 tumor growth is inhibited, anti-tumor T cell responses are not changed in LNs, and the growth of distal EG7 tumors is slightly reduced; Supplementary Figure 4 demonstrates that intratumoral CpG-B{plus minus}HY administration of MCA-101-Dby inhibits tumor growth and promote anti-tumor T cell immunity; Supplementary Figure 5 assesses the efficacy of pDC depletion in tumors from BDCA2-DTR mice injected with diphtheria toxin (DT); Supplementary Figure 6 shows that intratumoral CpG-B{plus minus}OVAII administration inhibits EG7 tumor growth in IFNAR-/- mice; Supplementary Figure 7 shows that CpG-B does not affect the phenotype and the function of tumor-associated neutrophils; Supplementary Figure 8 assesses the efficacy of neutrophil depletion in tumors following the injection of anti-Ly6G antibodies, and the impact on EG7 tumor weight. Supplementary Table Supplementary Table 1 shows the list of genes that are differentially expressed by tumor-associated cDC and/or tumor-associated pDC following intratumoral CpG-B administration. Genes were classified into 3 categories: Ag presentation-related genes, Immunogenicity-related genes, DC migration-related genes.